Filing Flows › Health Care › Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals (MIST) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Milestone Pharmaceuticals (MIST) Q2 2026 earnings results →
Milestone Pharmaceuticals made $559K in Q2 2026. Operating margin n/m, net loss $28.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $559K in Q2 2026, up 135% from the previous quarter.
Operating costs exceeded revenue by $25.6M, an operating margin of -4585.0%. The quarter ended with a net loss of $28.6M, wider than the previous quarter's $26.1M loss.
Operating cash flow was −$22.7M. Non-cash charges added back $57K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $4.5M. Capital expenditures of $26K exceeded it, leaving free cash flow of −$22.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $559K | — | n/m | −$28.6M | −$22.7M |
| Q1 2026 | 10-Q | May 13, 2026 | $238K | — | n/m | −$26.1M | −$16.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Milestone Pharmaceuticals
We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our approved product CARDAMYST TM (etripamil) nasal spray is available in the United States and is the first and only FDA approved self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. We continue to seek, either directly or through collaboration with our partners, marketing approval from regulatory agencies responsible for regions outside the United States. We are also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate, or “AFib-RVR.”
In its own words, from its 10-K, filed Mar 20, 2026.
Milestone Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MIST Milestone Pharmaceuticals | Q2 2026 | $559K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Milestone Pharmaceuticals 10-Q on SEC EDGAR · CIK 1408443 · Pharmaceutical Preparations
13F: who owns MIST and who is buying
More on MIST
- How Milestone Pharmaceuticals makes money: revenue by segment
- Milestone Pharmaceuticals next earnings date and what analysts expect
- Milestone Pharmaceuticals stock forecast, price target and fair value
- Who owns Milestone Pharmaceuticals stock: holders, funds and Congress trades
- Milestone Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results